newsfilter
← Latest News
PR Newswire·

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on...